A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Summary

This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).

Timeline

Start

2020-09-25

Primary completion

2022-06-10

Completion

2023-01-19

Publications

• Temkar S, Rajasekar G, Shah AD, Shaikh N, Deb AK, Basa K. Retinal vein occlusion-related macular edema: An updated review of current evidence and future directions. Indian J Ophthalmol. 2026 May 1;74(5):715-723. doi: 10.4103/IJO.IJO_3361_25. Epub 2026 Apr 29.

Drugs

Indications